Navigation Links
Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis therapeutics
Date:7/11/2011

PARIS, July 11, 2011 /PRNewswire/ -- Cellectis therapeutics, a subsidiary of Cellectis (Alternext: ALCLS) specializing in the development of therapeutic applications in genome engineering, today announced the appointment of Dr. Andrew M. Scharenberg as Chief Scientific Officer.

Dr. Scharenberg is an attending physician in Immunology at Seattle Children's Hospital, and Professor of Pediatrics and Immunology at the University of Washington. His academic laboratory is based at Seattle Children's Research Institute, and is world renowned for its work on the development of genome engineering technologies for innovative therapeutic applications.

Dr. Scharenberg is a principal investigator and codirector of the Northwest Genome Engineering Consortium (NGEC), which is focused on new approaches for treating genetic diseases. In addition, he is a cofounder and member of the Board of Director's of Pregenen Inc., a biotechnology spin-off from the NGEC, and a strategic partner of Cellectis focused on the commercial development of novel genome engineering technologies.

"We are thrilled that Andrew Scharenberg has accepted the post of Chief Scientific Officer of our therapeutic subsidiary," stated Chief Scientific Officer of the Cellectis group Frederic Paques. "His experience and energy will push our research teams to achieve their full potential."

About Cellectis therapeutics

Founded in 2008, Cellectis therapeutics is dedicated to the development of innovative therapeutic approaches that use meganucleases to treat genetic diseases, cancers, and persistent viral infections. Its prospective treatment targets the DNA sequence that causes disease, which may be innate (genetic disease) or acquired (viral infection, cancer). Cellectis therapeutics' aim is to fulfill unmet medical needs, giving patients new hope.

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

For further information about Cellectis, visit our website at: www.cellectis.com

Follow Cellectis on twitter : http://twitter.com/cellectis

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors
2. Andrew P. Mandell - Mr. Diabetes(R) to Sit On ProtoKinetix Advisory Board
3. Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club
4. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
5. Veridiam Appoints Andrew Gale as Chief Executive Officer
6. Andrew Chisholm Appointed Vice President, Sales and Corporate Accounts at Accumetrics
7. Algeta Appoints Andrew Kay as President and Chief Executive Officer
8. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
9. Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Companys Board of Directors
10. Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharmas Scientific and Medical Advisory Board
11. BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet ... innovative biopharmaceutical products for companion animals, will host a live ... ET to discuss financial results from the fourth quarter and ... participants and investors may access the audio webcast ... ...
(Date:2/22/2017)... ... , ... Park Systems , a leader in Atomic Force Microscopy (AFM) ... attendees and Park customers on Feb. 27, 2017 from 12-2pm at Morton’s The ... The luncheon will feature a talk on Automated AFM for Small-Scale and Large-Scale ...
(Date:2/22/2017)... Feb. 22, 2017 Scientists propose in ... organ damage in Gaucher and maybe other lysosomal storage ... lower costs than current therapies. An international ... Center , which also included investigators from the University ... their data Feb. 22. The study was conducted in ...
(Date:2/22/2017)... ... 22, 2017 , ... ProMIS Neurosciences (“ProMIS” or the “Company”), ... today announced it has issued a scientific white paper entitled “Results from recent ... of commentaries from ProMIS’s scientific team offering insight into the Company’s product portfolio ...
Breaking Biology Technology:
(Date:1/25/2017)... 25, 2017 The Elements of Enterprise Information ... is comprised of a comprehensive set of business ... maintaining digital identities and providing a secured and ... are significant number of programs opted by enterprises ... by optimizing processes and changing policies. However, there ...
(Date:1/21/2017)... DUBLIN , Jan 20, 2017 Research ... Recognition Biometrics Market 2017-2021" report to their offering. ... The global voice recognition ... period 2017-2021. The report covers the present scenario ... for 2017-2021. To calculate the market size, the report considers the ...
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
Breaking Biology News(10 mins):